Studies Currently Enrolling

Clinical trials are key to advancing the health care landscape and how we treat illnesses. Banner Alzheimer’s Institute (BAI) is proud to offer research studies to patients and people in the community. Studies here are focused on Alzheimer’s disease and other dementias. There are ways you can help research whether you have memory loss or not.

Below is a list of some of our ongoing clinical trials at Banner Alzheimer's Institute. You can also view the trials and studies at Banner Sun Health Research Institute here.

Phoenix, Ariz.

  • Studies for Participants Without Memory Loss

    • GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype (NCT02564692)
      Learn more: GeneMatch

    • TRC-PAD Program: In-Clinic Trial-Ready Cohort (TRC-PAD) (NCT04004767)
    • AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (NCT04468659)
    •  A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) (NCT05026866)

  • Studies for Participants With and Without Memory Loss

  • Studies for Participants With Memory Loss

    • Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (Hope4MCI) (NCT03486938)
    • A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (NCT04241068)
    • A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) (NCT04640077)
    • A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease (INVOKE-2) (NCT04592874)
    • New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study (NCT04426539)
    • Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ) (NCT05026177)
    • A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) (NCT04777396)
    • A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) (NCT04777409)

Tucson, Ariz.

  • Studies for Participants Without Memory Loss

    • A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) (NCT05026866

  • Studies for Participants With and Without Memory Loss

  • Studies for Participants With Memory Loss 

  • Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ) (NCT05026177)